The newly updated US Preventive Services Task Force recommendations on weight loss interventions are out. How will they impact your practice?
The US Preventive Services Task Force (USPSTF) recently released their updated recommendation statement on behavioral weight loss interventions for adults. What are the new recommendations? And how can they impact the primary care setting? Click through the slideshow above to get all the details.
FDA Accepts Protocol for Annovis Bio’s Buntanetap Phase 3 Alzheimer Disease Trial
January 9th 2025Buntanetap is an oral molecule designed to inhibit the production of multiple neurotoxic proteins and is under investigation for treatment of Alzheimer Disease, Parkinson’s Disease, and other neurodegenerative diseases.